Educational Needs in Hematopoietic Stem Cell Transplant: Eligibility Criteria, Transplant Benefits, and Risks

When patients with hematological malignancies do not receive referrals for hematopoietic stem cell transplant (HSCT), they may face a risk of poorer outcomes. Common reasons behind this lack of referrals include provider confusion over eligibility criteria for HSCT, overestimation of the risks associated with transplant, and confusion regarding the benefit of HSCT. This educational gap regarding the uses and risks of HSCT was identified in the baseline data collected from i3 Health's continuing ...
Continue reading

Inotuzumab Ozogamicin Effective in Ph-Positive Acute Lymphoblastic Leukemia

In patients with relapsed/refractory Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), inotuzumab ozogamicin increases rates of response, remission, hematopoietic stem cell transplantation (HSCT), and progression-free survival compared with intensive chemotherapy, although it does not produce a significant improvement in overall survival. "Historically, patients with Ph-positive ALL have had poorer prognoses, with higher rates of relapse and worse long-term survival ...
Continue reading

Treosulfan/Fludarabine Conditioning Improves Outcomes in HSCT

A recent phase 3 trial found that treosulfan/fludarabine used as conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (HSCT) led to greater event-free survival compared with busulfan/fludarabine in older or comorbid patients with acute myeloid leukemia or myelodysplastic syndrome. While patients age 50 or older with acute myeloid leukemia or myelodysplastic syndrome are often considered eligible for allogeneic HSCT, they are at increased risk from standard myeloabla...
Continue reading

Ruxolitinib Approved for Acute Graft-Versus-Host Disease

​The FDA has approved ruxolitinib (Jakafi®, Incyte Corporation), a JAK1/JAK2 inhibitor, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adults and in children age 12 and older. Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplantation (HSCT), a procedure involving the transfer of stem cells from a healthy donor to a patient with a hematologic malignancy following high-intensity chemotherapy or radiation. In GVHD, the donat...
Continue reading

Navigating the Therapeutic Landscape for Patients Undergoing HSCT With Sergio Giralt, MD

Hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow HSCT in older patients and alternative graft sources that afford a donor for nearly all patients who req...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.